## 1H-Indol-3-yl(pyridin-2-yl)methanol: A Versatile Building Block in Research
1H-Indol-3-yl(pyridin-2-yl)methanol is an organic compound with the chemical formula C14H12N2O. It features both an indole and a pyridine ring, which makes it a versatile building block for synthesizing various biologically active compounds.
**Why is it important for research?**
Here are some key areas where this compound is of interest:
* **Medicinal Chemistry:** The indole and pyridine moieties are commonly found in pharmaceuticals. 1H-Indol-3-yl(pyridin-2-yl)methanol can be used as a starting point for developing new drugs with various therapeutic activities, such as:
* **Anti-cancer agents:** The indole ring has been shown to exhibit anti-proliferative activity against several cancer cell lines.
* **Anti-inflammatory agents:** The pyridine ring is often found in anti-inflammatory drugs.
* **Antimicrobial agents:** Combining the indole and pyridine moieties can lead to compounds with antimicrobial properties.
* **Materials Science:** The compound's aromatic structure allows for potential applications in the development of organic semiconductors and photoactive materials.
* **Synthetic Chemistry:** 1H-Indol-3-yl(pyridin-2-yl)methanol serves as a valuable precursor for the synthesis of a wide range of heterocyclic compounds with diverse functionalities.
**Current research on 1H-Indol-3-yl(pyridin-2-yl)methanol:**
* **Synthesis and Characterization:** Researchers are actively exploring new and efficient synthetic routes to access this compound and its derivatives.
* **Biological Activity Studies:** The compound's potential therapeutic properties are being investigated through various biological assays, including cytotoxicity, antimicrobial, and anti-inflammatory studies.
* **Material Development:** Efforts are underway to explore the potential of this compound in organic electronics and optoelectronics.
**Challenges and Future Directions:**
* **Toxicity and Pharmacokinetic Studies:** More research is needed to evaluate the safety and pharmacokinetic properties of this compound and its derivatives before they can be considered for clinical trials.
* **Structure-Activity Relationship Studies:** Understanding the relationship between the structure of the compound and its biological activity is crucial for designing more potent and selective drugs.
* **Novel Applications:** Continued research may lead to the discovery of new and unexpected applications for this versatile compound.
Overall, 1H-Indol-3-yl(pyridin-2-yl)methanol holds immense potential in medicinal chemistry, materials science, and synthetic chemistry. Further research in these areas could lead to the development of new drugs, materials, and technologies with significant societal impact.
ID Source | ID |
---|---|
PubMed CID | 2810102 |
CHEMBL ID | 1376439 |
CHEBI ID | 190550 |
Synonym |
---|
STL305052 |
IFLAB1_005552 |
OPREA1_145765 |
MLS000043722 , |
smr000020734 |
1h-indol-3-yl(pyridin-2-yl)methanol |
IDI1_010955 |
SR-01000606017-2 |
AKOS000267243 |
HMS1427M08 |
CHEBI:190550 |
HMS2305B14 |
CCG-48407 |
(1h-indol-3-yl)(pyridin-2-yl)methanol |
F1310-0037 |
AKOS016038960 |
1h-indol-3-yl(2-pyridinyl)methanol |
1h-indol-3-yl(2-pyridyl)methanol |
cid_2810102 |
bdbm55268 |
CHEMBL1376439 |
(indol-3-yl)(pyridin-2-yl)methanol |
BRD-A27221145-001-08-7 |
51626-59-6 |
Z57213778 |
Class | Description |
---|---|
indoles | Any compound containing an indole skeleton. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 25.1189 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 89.1251 | 0.1000 | 20.8793 | 79.4328 | AID588453 |
Microtubule-associated protein tau | Homo sapiens (human) | Potency | 31.6228 | 0.1800 | 13.5574 | 39.8107 | AID1460 |
thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 22.3872 | 0.1000 | 22.9075 | 100.0000 | AID485364 |
nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 5.6234 | 0.2818 | 9.7212 | 35.4813 | AID2326 |
bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 89.1251 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
neutrophil cytosol factor 1 | Homo sapiens (human) | IC50 (µMol) | 50.0000 | 0.3900 | 6.5441 | 29.1200 | AID1275 |
Protein skinhead-1 | Caenorhabditis elegans | IC50 (µMol) | 100.0000 | 7.3900 | 21.5238 | 43.9000 | AID624474 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6 | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (12.50) | 29.6817 |
2010's | 5 (62.50) | 24.3611 |
2020's | 2 (25.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.17) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 8 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |